[Favorable outcome of gemcitabine-induced acute respiratory distress syndrome].
Gemcitabine is a new important drug used to treat solid tumors including non-small cell lung cancer, pancreatic, bladder and breast cancers. Myelosuppression is the most common adverse effect. Pulmonary toxicity is rare and usually mild and self-limiting with acute dyspnea. Severe pneumonitis and potentially fatal acute respiratory distress syndrome (ARDS) have been described in patients treated for a non-small cell lung cancer. We report a case of gemcitabine-induced ARDS in a 72-year old patient treated with gemcitabine and cisplatin for a bladder cancer without lung metastasis. Administration of high doses of corticosteroids led to a prompt symptomatic improvement.
Bonnichon
A
A
Service des Maladies Respiratoires, Hôpital d'Instruction des Armées Percy, 101, avenue Henri-Barbusse, 92140 Clamart. abpy@free.fr
Vedrine
L
L
Aletti
M
M
Le Moulec
S
S
Borne
M
M
Margery
J
J
Bauduceau
O
O
Fayolle
M
M
Ceccaldi
B
B
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D012128:Respiratory Distress Syndrome / Q000139:chemically induced* / Q000188:drug therapy*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy; D000093542:Gemcitabine
D000305:Adrenal Cortex Hormones; D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine